A Cautionary Note When Using Zonisamide in Youths: A Case Report of Association With Toxic Epidermal Necrolysis
J Clin Psychiatry 2004;65:1720-1720 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Sir: Zonisamide is a third-generation sulfonamide anticonvulsant indicated for treatment of partial seizures. As with other anticonvulsants, it has shown efficacy in treating bipolar disorder in adults1 and, unlike other agents, does not appear to cause weight gain. Zonisamide is contraindicated in patients with known sulfa allergies due to the risk of developing a medically